However, a post hoc analysis of large randomized placebo-controlled trials of antiresorptive therapies found that suppression of bone resorption, which significantly reduces the level of circulating osteocalcin, does not have a clinically important effect on fasting glucose or diabetes incidence (76). Here, BGLAP is linked to diabetes mellitus.